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Abstract
Background: Although highly active antiretroviral therapy (HAART) has improved HIV survival, some patients
receiving therapy are still dying. This analysis was conducted to identify factors associated with increased risk of
post-HAART mortality.
Methods: We evaluated baseline (prior to HAART initiation) clinical, demographic and laboratory factors (including
CD4+ count and HIV RNA level) for associations with subsequent mortality in 1,600 patients who began HAART in
a prospective observational cohort of HIV-infected U.S. military personnel.
Results: Cumulative mortality was 5%, 10% and 18% at 4, 8 and 12 years post-HAART. Mortality was highest (6.23
deaths/100 person-years [PY]) in those with ≤ 50 CD4+ cells/mm
3 before HAART initiation, and became progressively
lower as CD4+ counts increased (0.70/100 PY with ≥ 500 CD4+ cells/mm
3). In multivariate analysis, factors significantly
(p < 0.05) associated with post-HAART mortality included: increasing age among those ≥ 40 years (Hazard ratio [HR] =
1.32 per 5 year increase), clinical AIDS events before HAART (HR = 1.93), ≤ 50 CD4+ cells/mm
3 (vs. CD4+ ≥ 500, HR =
2.97), greater HIV RNA level (HR = 1.36 per one log10 increase), hepatitis C antibody or chronic hepatitis B (HR = 1.96),
and HIV diagnosis before 1996 (HR = 2.44). Baseline CD4+ = 51-200 cells (HR = 1.74, p = 0.06), and hemoglobin < 12
gm/dL for women or < 13.5 for men (HR = 1.36, p = 0.07) were borderline significant.
Conclusions: Although treatment has improved HIV survival, defining those at greatest risk for death after HAART
initiation, including demographic, clinical and laboratory correlates of poorer prognoses, can help identify a subset
of patients for whom more intensive monitoring, counseling, and care interventions may improve clinical
outcomes and post-HAART survival.
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Although highly active antiretroviral therapy (HAART)
has significantly reduced mortality in HIV-infected
patients [1-3], some patients receiving therapy are still
dying. Guidelines for patients on stable HAART recom-
mend laboratory monitoring and follow-up every 3-6
months [4]. However, more frequent and intensive mon-
itoring and care may be indicated for those at greatest
risk of post-HAART adverse clinical outcomes.
Although CD4+ count is an important determinant of
subsequent risk of death, other clinical and laboratory
parameters at HAART start, as well as factors such as
older age, may also affect post-HAART survival [5-10].
The U.S. Military HIV Natural History Study (NHS) is
a prospective observational cohort of consenting HIV-
infected military personnel [11]. Although HIV-positive
status is an exclusion criterion for enlistment, active
duty personnel undergo repeat HIV screening every 1-5
years, allowing for early diagnosis of infection; those
found HIV-positive after enlistment receive free HIV
specialty care, including HAART, at referral military
medical centers. With NHS participants now followed
for up to 14 years after HAART initiation, we examined
clinical, laboratory and demographic factors at HAART
initiation that were associated with subsequent mortality
Methods
Study cohort: We included active duty members and
retirees with: (1) documented HIV serostatus; (2) CD4+
count within six months before HAART; (3) HAART
initiation after July 1995, and after or within one month
before NHS enrollment. The governing central institu-
tional review board approved this substudy; NHS parti-
cipants provide written informed consent.
Variables for analysis: We evaluated death reports
from participating centers through November 2010. A
National Death Index (NDI) match was also conducted
to capture deaths through 12/31/06 among participants
lost to follow-up. Patients not known to have died who
remained under follow-up had follow-up period cen-
s o r e da td a t eo fl a s tc l i n i cv i s i t ;t h o s el o s tt of o l l o w - u p
had follow-up censored at 12/31/06 (corresponding to
NDI search).
“Baseline” for this analysis was date of HAART initia-
tion. Baseline CD4+ count and HIV RNA level were
values closest to HAART initiation in the six months
before HAART. Clinical AIDS events were those in the
Centers for Disease Control definition (CD4+ criteria
excluded) [12]. Anemia was defined as hemoglobin < 12
gm/dL for women and < 13.5 gm/dL for men within
three years before HAART. Body mass index (BMI) cal-
culations used height and weight within one year before
or up to 30 days after HAART initiation.
For 80% of participants with documented last negative
and first positive HIV test dates, estimated HIV SC date
was calculated as the midpoint. For 20%, date of first
positive but not last negative test was available; SC dates
were imputed based upon median times between last
negative and first positive date for other cohort mem-
bers with comparable first HIV positive dates [13].
Chronic hepatitis B virus (HBV) infection was defined
as ≥ 2 positive HBV surface antigen tests ≥ 6m o n t h s
apart, and hepatitis C virus (HCV) infection as a positive
HCV antibody test, both determined prior to or within
30 days of HAART initiation. We defined HAART
based on regimens with ≥ 2 ART classes or certain
combinations of ≥ 3 nucleoside/nucleotide reverse tran-
scriptase inhibitors (NRTI); other (non-HAART) ART
was essentially mono or dual therapy.
Statistical methods: Mortality rates following HAART
initiation were calculated per 100 person-years (PY)
with exact Poisson 95% confidence intervals (CI). We
used Kaplan-Meier summaries for cumulative mortality
rates post-HAART, and Cox proportional hazards mod-
els to estimate associations between baseline covariates
and mortality. Based upon visual evaluation of age at
HAART start and survival, linear splines were used to
model effects of age separately for those < 40 and ≥ 40
years of age.
Variables significant (p < 0.05) in univariate analyses
were included in the multivariate model. The proportional
hazards assumption was assessed by graphical inspection
of the log-negative-log of the survival distribution plotted
by log of survival time for covariate categories.
Results
Characteristics at HAART initiation: Table 1 sum-
marizes characteristics of 1,600 persons in this analysis.
Median time from estimated HIV SC to HAART initia-
tion was 4.8 years; median baseline values were: CD4+ =
326 cells/mm
3,H I VR N A=4 . 5l o g 10 copies/ml, BMI =
25.5 kg/m
2. Six percent were chronically infected with
HBV and 5% HCV antibody positive; 0.5% had both.
Initial HAART regimens were NRTI + protease inhibi-
tor for 59%, NRTI + non-nucleoside reverse transcrip-
tase inhibitor for 34%, and another regimen for 8%.
Mortality rates: Median follow-up post-HAART was
8.7 years, or 12,486 PY. During follow-up, there were
190 deaths, or 1.52 deaths per 100 PY (95% CI 1.31,
1.75). Cumulative mortality was 5% (95% CI 4%-6%) at
4 years, 10% (95% CI 9%-12%) at 8 years, and 18% (95%
CI 15%-20%) at 12 years. Mortality was highest in those
with ≤ 50 cells/mm
3 prior to HAART, and became pro-
gressively lower as CD4+ count increased (Table 1, Fig-
ure 1). Mortality rates progressively increased with
greater baseline HIV RNA levels and longer time from
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Page 2 of 7Table 1 Post-HAART Mortality Rate by Demographic, Clinical and Laboratory Parameters Prior to HAART Initiation, U.
S. Military HIV Natural History Study
Number and % of Participants Number of Deaths Deaths/100 PY (95% CI)
Gender
Male 1532 (96%) 182 1.53 (1.32, 1.77)
Female 68 (4%) 8 1.37 (0.59, 2.70)
Age at HAART Initiation (years)
< 29 395 (25%) 27 1.11 (0.73, 1.62)
29-33 371 (23%) 49 1.53 (1.13, 2.02)
34-39 454 (28%) 50 1.28 (0.95, 1.69)
≥ 40 380 (24%) 64 2.17 (1.67, 2.77)
Race
Caucasian 712 (45%) 81 1.40 (1.12, 1.75)
African American 686 (43%) 93 1.70 (1.38, 2.09)
Other 202 (13%) 16 1.27 (0.72, 2.06)
BMI at HAART initiation (kg/m
2)
< 25 642 (40%) 87 1.70 (1.36, 2.10)
25 to < 30 584 (37%) 54 1.23 (0.92, 1.61)
≥ 30 210 (13%) 16 1.07 (0.61, 1.74)
Unknown 164 (10%) 33 2.23 (1.54, 3.13)
Clinical AIDS event prior to HAART
No 1468 (92%) 138 1.20 (1.01, 1.42)
Yes 132 (8%) 52 5.23 (3.90, 6.85)
CD4+ count at HAART initiation (cells/mm
3)
≤ 50 112 (7%) 53 6.23 (4.67, 8.15)
51-200 259 (16%) 48 2.19 (1.61, 2.90)
201-349 517 (32%) 42 1.15 (0.83, 1.56)
350-499 433 (27%) 30 0.89 (0.60, 1.27)
≥ 500 279 (17%) 17 0.70 (0.41, 1.12)
HIV RNA at HAART initiation (copies/ml)
< 1000 139 (9%) 10 0.80 (0.38, 1.47)
1000-9999 316 (20%) 23 0.86 (0.55, 1.29)
10,000-99,999 752 (47%) 79 1.38 (1.09, 1.72)
≥ 100,000 393 (25%) 78 2.75 (2.18, 3.44)
Anemia within 3 years
No 941 (59%) 60 0.87 (0.66, 1.12)
Yes 635 (40%) 127 2.34 (1.95, 2.79)
Unknown 24 (2%) 3 1.96 (0.40, 5.73)
Chronic HBV or HCV antibody positive
No 1385 (87%) 138 1.29 (1.09, 1.53)
Yes 166 (10%) 48 3.44 (2.54, 4.56)
Unknown 49 (3%) 4 0.95 (0.26, 2.42)
Year of HIV diagnosis
Before 1996 848 (53%) 167 2.00 (1.71, 2.33)
1996 or after 752 (47%) 23 0.56 (0.35, 0.83)
Year of HAART initiation
Before 2000 967 (60%) 171 1.74 (1.49, 2.02)
2000-2010 633 (40%) 19 0.72 (0.43, 1.13)
Time from SC to HAART initiation (years)
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baseline factors are in Table 1.
Predictors of mortality: In univariate analysis, partici-
pants with CD4+ ≤ 50 cells/mm
3 and 51-200 cells/mm
3
at HAART initiation had significantly (p < 0.05)
increased mortality compared to ≥ 500 CD4+ cells
(Table 2). Mortality significantly increased with older
age among those ≥ 40 years, but not among those < 40
years. Other factors significantly associated with
increased mortality included clinical AIDS events before
HAART, greater HIV RNA levels, anemia, HCV/chronic
HBV, HIV diagnosis before 1996, HAART initiation
before 2000, longer time from SC to HAART initiation,
and non-HAART ART use (Table 2).
Exploratory analysis found strong colinearity between
years from SC to HAART initiation, HIV diagnosis era,
era of HAART initiation, and other ART use. For multi-
variate models, we chose HIV diagnosis before or after
1996, when HAART generally became available. Multi-
variate factors significantly associated with mortality
included: increasing age among those ≥ 40 years, clinical
AIDS event before HAART, CD4+ ≤ 50 cells/mm
3,
greater HIV RNA level, HCV/chronic HBV, and HIV
diagnosis before 1996 (Table 2). Anemia within three
years prior to HAART (p = 0.07), and CD4+ = 51-200
cells/mm
3 (p = 0.06) were of borderline significance.
In additional exploratory analyses, we added gender
and race (as potential confounders), or initial HAART
regimen class to our multivariate model; none of these
was significantly associated with mortality.
Discussion
Among HIV-infected military personnel, factors at
HAART initiation associated with poorer survival
included greater age in those ≥ 40 years, lower CD4+
count, greater HIV RNA level, prior clinical AIDS event,
Table 1 Post-HAART Mortality Rate by Demographic, Clinical and Laboratory Parameters Prior to HAART Initiation, U.
S. Military HIV Natural History Study (Continued)
< 2 473 (30%) 16 0.55 (0.31, 0.89)
2-5 353 (22%) 31 1.20 (0.82, 1.71)
5 to < 9 383 (24%) 64 1.83 (1.41, 2.33)
≥ 9 391 (24%) 79 2.26 (1.79, 2.82)
Other (non-HAART) ART
No 835 (52%) 30 0.61 (0.41, 0.87)
Yes 765 (48%) 160 2.12 (1.80, 2.48)
Figure 1 Cumulative Proportion Surviving by Baseline CD4+ Count Prior to HAART Initiation, U.S. Military HIV Natural History Study.
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HBV; in multivariate analysis, anemia was borderline
significant.
Consistent with other studies [14-16], mortality rates pro-
gressively decreased from lowest to highest baseline CD4+
strata, from 6.23 deaths in ≤ 50 CD4+ cell strata to 0.70
deaths/100 PY in the ≥ 500 CD4+ strata. While we did not
find statistically significant mortality differences between
higher CD4+ levels [8], this may reflect limited power from
smaller numbers of deaths in higher CD4+ categories.
Higher HIV RNA level prior to HAART predicted
increased mortality even after adjusting for CD4+ count
Table 2 Univariate and Multivariate Model Estimates for Post-HAART Mortality by Baseline Parameters Prior to HAART
Initiation, U.S. Military HIV Natural History Study
Baseline Covariate (at HAART initiation) Univariate Hazard Ratio (95% CI) Multivariate Hazard Ratio (95% CI)
Gender: Female vs. Male 0.89 (0.44, 1.80) —†
Age:
per 5 years older if age < 40 years 1.11 (0.95, 1.30) 0.91 (0.76, 1.08)
per 5 years older if age ≥ 40 years 1.27 (1.12, 1.44)** 1.32 (1.16, 1.51)**
Race
Caucasian 1.00 (Reference) —†
African American 1.22 (0.91, 1.65) —†
Other 0.92 (0.54, 1.58) —†
BMI
< 25 1.00 (Reference) —†
25 to < 30 0.73 (0.52, 1.03) —†
≥ 30 0.64 (0.38, 1.10) —†
Unknown 1.29 (0.87, 1.93) —†
Clinical AIDS event prior to HAART 4.26 (3.09, 5.87)** 1.93 (1.33, 2.81)**
CD4+ count at (cells/mm
3)
≤ 50 8.91 (5.15, 15.40)** 2.97 (1.56, 5.65)**
51-200 3.07 (1.76, 5.35) ** 1.74 (0.97, 3.12)
201-349 1.69 (0.96, 2.98) 1.39 (0.79, 2.46)
350-499 1.29 (0.71, 2.35) 1.21 (0.66, 2.19)
≥ 500 1.00 (Reference) 1.00 (Reference)
HIV RNA (copies/ml) per one log10 increase 1.72 (1.44, 2.04)** 1.36 (1.12, 1.64)*
Anemia within 3 years
No 1.00 (Reference) 1.00 (Reference)
Yes 2.61 (1.92, 3.55)** 1.36 (0.97, 1.92)
Unknown 2.29 (0.72, 7.30) 1.96 (0.40, 5.73)
Chronic HBV or HCV antibody positive
No 1.00 (Reference) 1.00 (Reference)
Yes 2.61 (1.88, 3.63)** 1.96 (1.39, 2.76)**
Unknown 0.73 (0.27, 1.99) 0.98 (0.36, 2.67)
Year of HIV diagnosis
Before 1996 3.35 (2.16, 5.21)** 2.44 (1.51, 3.93)**
1996 or after 1.00 (Reference) 1.00 (Reference)
Year of HAART initiation
Before 2000 2.13 (1.31, 3.46)* —† †
2000-2010 1.00 (Reference) —† †
Time from SC to HAART (years) per 1 year increase 1.10 (1.06, 1.14)** —† †
Other (non-HAART) ART 3.28 (2.21, 4.87)** —† †
* p = 0.002 ** p < 0.001
† Multivariate model included only variables significant in univariate analysis
†† Not included in multivariate model because of strong collinearity with Year of HIV diagnosis
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those with higher HIV RNA levels had longer time to
viral suppression after HAART initiation, and/or did not
develop viral suppression before death. Ongoing HIV
replication may place patients at greater risk of opportu-
nistic disease or death [17,18].
Among those ≥ 40 years, older age at HAART start
was associated with poorer prognosis. Other analyses of
HIV patients in the HAART era also report decreased
survival with older age [8-10,18]. Given increasing
recognition of HIV in those ≥ 50 years [19,20], older
patients initiating HIV care and treatment require more
intensive monitoring and follow-up.
In this analysis, we combined chronic HBV and HCV
antibody positivity, since HIV patients co-infected with
either virus have increased mortality from liver-related
deaths [21-23]. Although we did not have access to
HCV RNA, the great majority of HCV antibody-positive
HIV patients likely had chronic HCV infection [23,24].
Providers should know current guidelines for co-
infected patient including, when appropriate, therapy
against HBV or HCV [4,23,25].
This cohort of HIV-infected military personnel has
several strengths. Medical and other support provided
to participants (including free HIV treatment) minimize
socioeconomic disadvantage and lack of access to care
that might otherwise influence outcome. Viral suppres-
sion rates in this cohort were reported to approach
those in clinical trials [11]. The cohort is ethnically
diverse. We can estimate time from HIV SC to HAART
start. Follow-up extended for some patients to 14 years,
longer than many other studies.
Our analysis has several limitations. We focused on
baseline factors at HAART initiation, and not time-
updated post-HAART changes. Our endpoint was over-
all mortality, rather than specific causes of death. Group
differences in mortality may be due to additional
unmeasured confounding factors. Populations with dif-
ferent demographic or risk characteristics may have dif-
ferent predictors of survival.
In summary, although HAART has improved survival
for persons with HIV, defining those at greatest risk for
death after HAART initiation, including demographic,
clinical and laboratory indicators associated with poorer
prognoses, can help identify a subset of patients for
whom more intensive monitoring, counseling, and care
interventions may improve clinical outcomes and post-
HAART survival.
Acknowledgements and funding
Additional members of the Infectious Disease Clinical Research Program HIV/
STI Working Group include Susan Banks, Mary Bavaro, Helen Chun, Cathy
Decker, Connor Eggleston, Susan Fraser, Joshua Hartzell, Gunther Hsue,
Arthur Johnson, Mark Kortepeter, Tahaniyat Lalani, Michael Landrum,
Michelle Linfesty, Scott Merritt, Robert O’Connell, Sheila Peel, Michael Polis,
Roseanne Ressnerk, Edmund Tramont, Tyler Warkentien, Paige Waterman,
Amy Weintrob, Timothy Whitman, Glenn Wortmann, and Michael Zapor. The
content and views expressed in this publication is the sole responsibility of
the authors and does not necessarily reflect the views or policies of the NIH
or the Department of Health and Human Services, the DoD or the
Departments of the Army, Navy, Air Force, Department of Defense, nor the
U.S. Government. Mention of trade names, commercial products, or
organizations does not imply endorsement by the U.S. Government. Support
for this work (IDCRP-000-14) was provided by the Infectious Disease Clinical
Research Program, a Department of Defense (DoD) program executed
through the Uniformed Services University of the Health Sciences. This
project has been funded in whole, or in part, with federal funds from the
National Institute of Allergy and Infectious Diseases, National Institutes of
Health (NIH), under Inter-Agency Agreement Y1-AI-5072.
Author details
1Division of Epidemiology and Community Health, University of Minnesota,
Minneapolis, MN, USA.
2Division of Biostatistics, University of Minnesota,
Minneapolis, MN, USA.
3Infectious Disease Clinical Research Program,
Uniformed Services University of Health Sciences, Bethesda, MD, USA.
4Infectious Disease, Naval Medical Center San Diego, San Diego, CA, USA.
5Infectious Disease, National Naval Medical Center, Bethesda, MD, USA.
6Infectious Disease Service, San Antonio Military Medical Center, San
Antonio, TX, USA.
7National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, MD, USA.
Authors’ contributions
AL was lead author on planning and coordinating the analysis, and drafting
interim and final versions of the manuscript. EK, PG, AE, and LE provided
statistical support and assistance with various aspects of the analysis. GM,
NC, AG, JO, BA had multiple responsibilities related to this cohort, including
data collection and oversight at study sites at which participants were
followed. Co-authors all provided feedback and offered valuable comments
and suggestions on versions of this manuscript. All co-authors have seen
and approved the final version of this manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 19 September 2011 Accepted: 10 February 2012
Published: 10 February 2012
References
1. Mocroft A, Ledergerber B, Katlama C, et al: Decline in the AIDS and death
rates in the EuroSIDA study: an observational study. Lancet 2003,
362:22-9.
2. Walensky RP, Paltiel AD, Losina E, et al: The survival benefits of AIDS
treatment in the United States. J Infect Dis 2006, 194:11-9.
3. Lohse N, Hansen AB, Pedersen G, et al: Survival of persons with and
without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007,
146:87-95.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines
for the use of antiretroviral agents in HIV-1-infected adults and
adolescents. Dept. Health and Human Services; 2011, 1-167[http://www.
aidsinfo.nih.gov/Contentfiles/AdultandAdolescentGL.pdf].
5. Harris RJ, Sterne JA, Abgrall S, et al: Prognostic importance of anaemia in
HIV type-1-infected patients starting antiretroviral therapy: collaborative
analysis of prospective cohort studies. Antivir Ther 2008, 13:959-67.
6. Moh R, Danel C, Messou E, et al: Incidence and determinants of mortality
and morbidity following early antiretroviral therapy initiation in HIV-
infected adults in West Africa. AIDS 2007, 21:2483-91.
7. Jaen A, Esteve A, Miro JM, et al: Determinants of HIV progression and
assessment of the optimal time to initiate highly active antiretroviral
therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr 2008,
47:212-20.
8. Kitahata MM, Gange SJ, Abraham AG, et al: Effect of early versus deferred
antiretroviral therapy for HIV on survival. N Engl J Med 2009, 360:1815-26.
9. May M, Boulle A, Phiri S, et al: Prognosis of patients with HIV-1 infection
starting antiretroviral therapy in sub-Saharan Africa: a collaborative
analysis of scale-up programmes. Lancet 2010, 376:449-57.
Lifson et al. AIDS Research and Therapy 2012, 9:4
http://www.aidsrestherapy.com/content/9/1/4
Page 6 of 710. Lima VD, Hogg RS, Harrigan PR, et al: Continued improvement in survival
among HIV-infected individuals with newer forms of highly active
antiretroviral therapy. AIDS 2007, 21:685-92.
11. Marconi VC, Grandits GA, Weintrob AC, et al: Outcomes of highly active
antiretroviral therapy in the context of universal access to healthcare:
the U.S. Military HIV Natural History Study. AIDS Res Ther 2010, 7:14.
12. Centers for Disease Control: 1993 revised classification system for HIV
infection and expanded surveillance case definition for AIDS among
adolescents and adults. Morbid Mortal Wkly Rep 1992, 41(RR-17):1-19.
13. Lifson AR, Krantz EM, Eberly LE, et al: Long-term CD4+ lymphocyte
response following HAART initiation in a U.S. Military prospective cohort.
AIDS Res Ther 2011, 8:2.
14. When to Start Consortium: Timing of initiation of antiretroviral therapy in
AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV
cohort studies. Lancet 2009, 373:1352-63.
15. The Antiretroviral Therapy Cohort Collaboration (ART-CC): Prognosis of
patients treated with cART from 36 months after initiation, according to
current and previous CD4 cell count and plasma HIV-1 RNA
measurements. AIDS 2009, 23:2199-208.
16. The HIV-CAUSAL Collaboration: The effect of combined antiretroviral
therapy on the overall mortality of HIV-infected individuals. AIDS 2010,
24:123-37.
17. The Strategies for Management of Antiretroviral Therapy (SMART) Study
Group: Inferior clinical outcome of the CD4+ cell count-guided
antiretroviral treatment interruption strategy in the SMART study: role of
CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis 2008,
197:1145-55.
18. Mugavero MJ, Napravnik S, Cole SR, et al: Viremia copy-years predicts
mortality among treatment-naive HIV-infected patients initiating
antiretroviral therapy. Clin Infect Dis 2011, 53:927-35.
19. Zhao H, Goetz MB: Complications of HIV infection in an ageing
population: challenges in managing older patients on long-term
combination antiretroviral therapy. J Antimicrob Chemother 2011,
66:1210-14.
20. Althoff KN, Gebo KA, Gange SJ, et al: CD4 count at presentation for HIV
care in the United States and Canada: Are those over 50 years more
likely to have a delayed presentation? AIDS Res Ther 2010, 7:45.
21. Weber R, Sabin CA, Friis-Moller N, et al: Liver-related deaths in persons
infected with the human immunodeficiency virus: the D:A:D study. Arch
Intern Med 2006, 166:1632-41.
22. Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M: Risk of
hepatitis-related mortality increased among hepatitis C virus/HIV-
coinfected drug users compared with drug users infected only with
hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr
2008, 47:221-5.
23. Thio CL: Hepatitis B and human immunodeficiency virus coinfection.
Hepatology 2009, 49(5 Suppl):S138-45.
24. Thomas DL, Astemborski J, Rai RM, et al: The natural history of hepatitis C
virus infection: host, viral, and environmental factors. JAMA 2000,
284:450-6.
25. Sulkowski MS, Cheever LW, Spach DH: A guide for evaluation and
treatment of hepatitis C in adults coinfected with HIV. U.S. Dept. Health
and Human Services, Health Resources and Services Administration; 2011
[http://hab.hrsa.gov/deliverhivaidscare/files/hepccoinfectguide2011.pdf].
doi:10.1186/1742-6405-9-4
Cite this article as: Lifson et al.: Clinical, demographic and laboratory
parameters at HAART initiation associated with decreased post-HAART
survival in a U.S. military prospective HIV cohort. AIDS Research and
Therapy 2012 9:4. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lifson et al. AIDS Research and Therapy 2012, 9:4
http://www.aidsrestherapy.com/content/9/1/4
Page 7 of 7